| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |